Carregando empresa
Keep exploring
The themes Sanofi is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$ 1,36TA+
JNJJohnson & JohnsonUS$ 688,6BA+
MRKMerck & Co., Inc.US$ 364,3BA
NVSNovartis AGUS$ 306,3BA
AMGNAmgen Inc.US$ 251,9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 de out. de 2026CAGraded C, now A
Como ganha dinheiro
- Prescription medicines
- Vaccines
Concorre com
O que vende5
Dupixent
A biologic medicine used for several conditions; the call mentions its approval for chronic spontaneous urticaria in children.
ALTUVIIIO
A medicine for hemophilia A, a disorder that affects blood clotting.
AYVAKIT
A medicine used to treat systemic mastocytosis, a rare disease.
Mostrar mais 2
Sarclisa
A medicine for multiple myeloma, a cancer of plasma cells.
Wayrilz
A medicine approved in Japan for immune thrombocytopenia, a condition involving low levels of platelets in the blood.
Quem compra3
- Patients receive Sanofi medicines through healthcare professionals who prescribe or administer them.
- People receive Sanofi vaccines through healthcare providers and public health programs.
- Pharmacies and clinics are involved in medicine access programs.
Em que se apoia e o que pode quebrá-lo
Do que o negócio depende
- 1Dupixent is developed with Regeneron under an alliance that Sanofi describes as strategically important.
- 2Vaccine sales vary with seasonal demand, including the timing and strength of influenza seasons.
- 3Sanofi depends on clinical studies to show that medicines in development work well enough to advance.
O que pode dar errado
- 1Sanofi says its global business exposes it to increased risks in specific areas.
- 2Clinical setbacks have included failed or discontinued studies involving Dupixent in lichen simplex chronicus, venglustat in Fabry disease, and other pipeline medicines.
- 3Sanofi and Regeneron have ongoing litigation over information sharing, while discussions about future collaboration continue without a reported agreement.
Demonstrações financeiras completas →
Sobre a Sanofi
Sanofi makes prescription medicines and vaccines. Its medicines treat conditions including hemophilia A, systemic mastocytosis, and multiple myeloma. It also develops new medicines and vaccines through clinical trials.
- Sede
- Paris, France
- Fundada em
- 1973 (founding year, high)
- Listada em
- NYSE
- Fim do exercício
- December 31
Construído a partir dos próprios documentos de Sanofi entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Esta empresa divulga em EUR. Os números são convertidos para dólares a US$ 1,00 = 0,904810 EUR, a taxa atual, aplicada igualmente a todos os períodos — assim o crescimento e as margens são da empresa e não do câmbio. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
